|
FORX-428 Clinical Trials
1 actively recruiting trial across 1 location
Palo Alto, California1 trial
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
Stanford University Medical Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.